Comprehensive review of SBRT in oligomestatic PCa patients. Please note the potential bias in the individual studies used (". . .12 were retrospective and only one was a randomised controlled trial.") From the review paper:
. . .
SBRT uses highly conformal and precisely targeted radiation delivered in a very dose-intensive pattern (10) and is emerging as a low-toxicity treatment option for prostatic oligometastases that can potentially eliminate all macroscopic cancer foci; thereby prolonging the progression-free interval and postponing ADT. The concept of ADT-free survival (ADT-FS) is defined as the time to the delayed start of ADT, and is a method to spare the known negative side effects of systemic therapy in patients with metastatic cancer, such as increased occurrence of cardiovascular events and metabolic syndrome (11).
Confirming the benefits of SBRT in oligometastatic prostate cancer might shift the treatment paradigm from palliative to a potentially curable disease in a subset of patients. However, to date, there is a paucity of randomised studies in which SBRT is compared with standard of care management.
The aim of this review was to evaluate the efficacy of SBRT among patients with oligometastatic prostate cancer, and to ascertain if the treatment outcome was improved by using SBRT in terms of ADT-FS, progression-free survival (PFS) rate, and local control rate (LCR) and to compare the toxicity profile of SBRT to that of standard of care management.
. . .
Abstract is here:
ar.iiarjournals.org/content...
And full study via Sci-Hub is here:
sci-hub.uno/10.21873/antica...
Be Well - Captain K9
Welcoming New Era of Expanded Use of Radiotherapies
